Related Experiment Video
Updated: Jun 16, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data
Patrick M Dillon1, Christiana M Brenin1, Craig L Slingluff2
1University of Virginia, Division of Hematology/Oncology, Charlottesville, VA 22908, USA.
Abstract:
Vaccine therapies for treatment and prevention of cancer have seen modest degrees of efficacy with wide variation related to the tumor type, vaccine type, adjuvants and clinical setting for their study. Over the course of the last two decades, various peptide vaccines for breast cancer have been studied. The current leading peptide vaccine for human application is a HER2-based vaccine known as Nelipepimut-S, which has demonstrated immune activity and promising clinical activity in some settings. This review covers the development of this newer peptide vaccine for both HER2 amplified and non-amplified breast cancer.
Insights
Nelipepimut-S is a promising HER2-based peptide vaccine for breast cancer treatment and prevention. This review details its development for both HER2-amplified and non-amplified tumors.
Area of Science:
- Oncology
- Immunotherapy
- Vaccine Development
Background:
- Cancer vaccine therapies show variable efficacy depending on tumor type, vaccine, adjuvants, and clinical context.
- Peptide vaccines targeting HER2 have been investigated for breast cancer over the past 20 years.
- Nelipepimut-S is a leading HER2-based peptide vaccine demonstrating immune and clinical activity.
Purpose of the Study:
- To review the development of Nelipepimut-S, a novel peptide vaccine for breast cancer.
- To discuss its application in both HER2-amplified and HER2-non-amplified breast cancer.
- To highlight its potential in cancer immunotherapy.
Main Methods:
- Literature review of studies on peptide vaccines for breast cancer.
- Focus on HER2-based vaccines, particularly Nelipepimut-S.
- Analysis of clinical data regarding efficacy and immune response.
Main Results:
- Nelipepimut-S has shown immune activity in clinical studies.
- Promising clinical activity has been observed in specific settings.
- The vaccine is being developed for both HER2-amplified and non-amplified breast cancer.
Conclusions:
- Nelipepimut-S represents a significant advancement in HER2-targeted breast cancer vaccines.
- Further development is warranted to optimize its use in diverse breast cancer subtypes.
- Peptide vaccines hold potential for improved cancer treatment and prevention strategies.
